SPY316.18+2.40 0.76%
DIA260.72+1.68 0.65%
IXIC10,492.50+148.61 1.44%

Canaccord Genuity Maintains Buy on Harpoon Therapeutics, Lowers Price Target to $22

Canaccord Genuity maintains Harpoon Therapeutics (NASDAQ:HARP) with a Buy and lowers the price target from $24 to $22.

Benzinga · -

Canaccord Genuity maintains Harpoon Therapeutics (NASDAQ:HARP) with a Buy and lowers the price target from $24 to $22.